EGFR and lung adenocarcinoma: Lung adenocarcinoma (LUAD) demonstrated a contrasting pattern, where elevated HuR linked to reduced WEE1 inhibitor (MK-1775) efficacy (R = -0.28, p < 0.01) but enhanced sensitivity to platinum agents (Cisplatin) and wild-type EGFR-TKIs (Erlotinib; R = 0.35-0.42, p < 0.01).